Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Nektar Therapeutics Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$2.96 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 17, 2020	SELL	$15.87 - $23.12 $168,047 - $244,817	-10,589 Closed	0 $0
Q3 2019 Oct 29, 2019	BUY	$16.91 - $36.27 $57,138 - $122,556	3,379 Added 46.87%	10,589 $189,000
Q1 2019 Apr 29, 2019	BUY	$31.58 - $46.35 $227,691 - $334,183	7,210 New	7,210 $236,000

Others Institutions Holding NKTR

# of Institutions

140

Shares Held

135M

Call Options Held

32.8K

Put Options Held

55.5K

Deep Track Capital, LP Greenwich, CT

17.9M
Shares

$23.2 Million
0.73% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$19.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13M
Shares

$16.9 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.46M
Shares

$12.3 Million
0.21% of portfolio
Eventide Asset Management, LLC Boston, MA

7.53M
Shares

$9.79 Million
0.16% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account